Roivant Sciences Ltd. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
$ROIV
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2025
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of Principal Executive Offices)
+44 207 400-3347
(Registrant’s Telephone Number, Including Area Code)
Former Name or Former Address, if Changed Since Last Report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 16, 2025, Roivant Sciences, Inc. (“RSI”), a wholly-owned subsidiary of Roivant Sciences Ltd. (the “Company”), entered into a consulting agreement
(the “Consulting Agreement”) with its former Chief Accounting Officer, Rakhi Kumar. As previously disclosed in a Current Report on Form 8-K filed on February 21, 2025, Ms. Kumar stepped down from her role effective February 20, 2025. Under the
Consulting Agreement, Ms. Kumar will provide certain advisory and transition services as may be reasonably requested by RSI from time to time (the “Services”). In consideration for the Services, the Consulting Agreement provides that Ms. Kumar will
be eligible to continue to vest into her outstanding Company equity incentive awards during the 18-month term of the Consulting Agreement (the “Term”). At the conclusion of the Term, provided that Ms. Kumar has complied with her obligations under the
Consulting Agreement and the other documentation entered into in connection with her separation from RSI, and that the Consulting Agreement is not otherwise earlier terminated in accordance with its terms, any Company equity incentive awards held by
Ms. Kumar that remain outstanding and unvested at such time shall fully vest as of such date.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No.
|
Description
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
ROIVANT SCIENCES LTD.
|
||
|
Date: March 20, 2025
|
By:
|
/s/ Keyur Parekh
|
|
Name: Keyur Parekh
|
||
|
Title: Authorized Signatory
|
||